Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Sage Therapeutics (SAGE)

Sage Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SAGE
DateTimeSourceHeadlineSymbolCompany
07/05/202411:30Business WireSage Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
25/04/202411:30Business WireSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressNASDAQ:SAGESage Therapeutics Inc
17/04/202411:30Business WireSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s DiseaseNASDAQ:SAGESage Therapeutics Inc
11/04/202411:30Business WireSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024NASDAQ:SAGESage Therapeutics Inc
28/02/202411:30Business WireSage Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
21/02/202421:35Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
15/02/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
15/02/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
14/02/202421:09Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
14/02/202412:49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SAGESage Therapeutics Inc
14/02/202412:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SAGESage Therapeutics Inc
14/02/202411:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
14/02/202411:30Business WireSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business ProgressNASDAQ:SAGESage Therapeutics Inc
31/01/202422:25Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:SAGESage Therapeutics Inc
31/01/202421:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
31/01/202411:30Business WireSage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024NASDAQ:SAGESage Therapeutics Inc
24/01/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
23/01/202413:13Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:SAGESage Therapeutics Inc
08/01/202411:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAGESage Therapeutics Inc
08/01/202411:32Business WireSage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SAGESage Therapeutics Inc
08/01/202411:30Business WireSage Therapeutics Announces Changes to Board of DirectorsNASDAQ:SAGESage Therapeutics Inc
04/01/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAGESage Therapeutics Inc
02/01/202411:30Business WireSage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024NASDAQ:SAGESage Therapeutics Inc
19/12/202313:32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SAGESage Therapeutics Inc
19/12/202313:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SAGESage Therapeutics Inc
14/12/202311:30GlobeNewswire Inc.ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:SAGESage Therapeutics Inc
14/12/202311:30Business WireZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:SAGESage Therapeutics Inc
08/12/202314:00Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:SAGESage Therapeutics Inc
08/12/202313:30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SAGESage Therapeutics Inc
08/11/202311:30Business WireSage Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SAGESage Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SAGE